Motesanib (AMG-706)是ATP竞争性VEGFR1,2,3抑制剂,IC50分别为 2 nM,3 nM和6 nM,对c-Kit的IC50为8 nM。
别名:AMG 706
In vitro: Motesanib Diphosphate has broad activity against the human VEGFR family, and displays >1000 selectivity against EGFR, Src, and p38 kinase. Motesanib Diphosphate significantly inhibits VEGF-induced cellular proliferation of HUVECs with an IC50 of 10 nM, while displaying little effect at bFGF-induced proliferation with an IC50 of >3,000 nM. Motesanib Diphosphate also potently inhibits PDGF-induced proliferation and SCF-induced c-kit phosphorylation with IC50 of 207 nM and 37 nM, respectively, but not effective against the EGF-induced EGFR phosphorylation and cell viability of A431 cells. Althouth displaying little antiproliferative activity on cell growth of HUVECs alone, Motesanib Diphosphate treatment significantly sensitizes the cells to fractionated radiation. In vivo: Administration of Motesanib Diphosphate at 100 mg/kg significantly inhibits VEGF-induced vascular permeability in a time-dependent manner. Oral administration of Motesanib Diphosphate twice daily or once daily potently inhibits, in a dose-dependent manner, VEGF-induced angiogenesis using the rat corneal model with ED50 of 2.1 mg/kg and 4.9 mg/kg, respectively. Motesanib Diphosphate induces a dose-dependent tumor regression of established A431 xenografts by selectively targeting neovascularization in tumor cells. Administration of Motesanib Diphosphate in combination with radiation displays significant anti-tumor activity in head and neck squamous cell carcinoma (HNSCC) xenograft models. Motesanib Diphosphate treatment also induces significant dose-dependent reductions in tumor growth and blood vessel density of MCF-7, MDA-MB-231, or Cal-51 xenografts, which can be markedly enhanced when combined with docetaxel or tamoxifen.
分子量 | 373.45 |
分子式 | C22H23N5O |
CAS号 | 453562-69-1 |
性状 | Solid |
溶解性(25°C) | ≥ 30 mg/mL in DMSO |
储存条件 |
粉末型式 -20°C 3年;4°C 2年 溶于溶剂 -80°C 6个月;-20°C 1个月 |
运输方式 | 冰袋运输,根据产品的不同,可能会有相应调整。 |
*下述溶液配置方法仅为基于分子量计算出的理论值。不同产品在配置溶液前,需考虑其在不同溶剂中的溶解度限制。
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.6777 mL | 13.3887 mL | 26.7773 mL |
5 mM | 0.5355 mL | 2.6777 mL | 5.3555 mL |
10 mM | 0.2678 mL | 1.3389 mL | 2.6777 mL |
小鼠 | 大鼠 | 兔 | 豚鼠 | 仓鼠 | 狗 | |
重量 (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
体表面积 (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km 系数 | 3 | 6 | 12 | 8 | 5 | 20 |
动物 A (mg/kg) = 动物 B (mg/kg) × | 动物 B的Km系数 |
动物 A的Km系数 |
例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。
其他相关的c-Kit产品 |
---|
Labuxtinib
Labuxtinib 是 c-kit 酪氨酸激酶抑制剂。 |
Elenestinib phosphate
Elenestinib phosphate (BLU-263 phosphate) 是一种有效的口服活性酪氨酸激酶 (b>tyrosine kinase) 抑制剂。Elenestinib phosphate 具有研究系统性肥大细胞增多症(SM)的潜力。 |
Elenestinib
Elenestinib (BLU-263 ) 是一种有效的口服活性酪氨酸激酶 (b>tyrosine kinase) 抑制剂。Elenestinib 具有研究系统性肥大细胞增多症(SM)的潜力。 |
Bezuclastinib
Bezuclastinib (CGT9486; PLX 9486) 是一种有效的 c-kit 和c-kit D816V 抑制剂,0.0001 < IC50 < 1 μM。Bezuclastinib 是一种酪氨酸激酶抑制剂。 |
Amuvatinib hydrochloride
Amuvatinib hydrochloride (MP470 hydrochloride) 是一种多靶点酪氨酸激酶抑制剂,对突变 c-Kit,PDGFRα,Flt3,c-Met 和 c-Ret 具有有效活性。Amuvatinib hydrochloride (MP470 hydrochloride) 还是一种 DNA 修复抑制剂,靶向蛋白 DNA 修复 RAD51,从而破坏 DNA 损伤修复。具有抗肿瘤活性。 |
产品仅供科学研究或药证申报的用途使用,不为任何个人或者非科研性质的其他用途提供服务。
Copyright © 2010-2022 AbMole版权所有 沪ICP备16047849号 沪公网安备 31011502012228号